Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Leslie Citrome. (2023) Vive la révolution! a paradigm shift in the pharmacological treatment of schizophrenia. Current Medical Research and Opinion 39:3, pages 473-474.
Read now
Read now
Leslie Citrome. (2018) Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy. Neuropsychiatric Disease and Treatment 14, pages 2563-2577.
Read now
Read now
Leslie Citrome. (2018) Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective. Expert Review of Neurotherapeutics 18:4, pages 323-332.
Read now
Read now
Leslie Citrome, Anna Eramo, Clement Francois, Ruth Duffy, Susan N Legacy, Steve J Offord, Holly B Krasa, Stephen S Johnston, Alice Guiraud-Diawara, Siddhesh A Kamat & Patricia Rohman. (2015) Lack of tolerable treatment options for patients with schizophrenia. Neuropsychiatric Disease and Treatment 11, pages 3095-3104.
Read now
Read now
Leslie Citrome. (2014)
Asenapine review, part II: clinical efficacy, safety and tolerability. Expert Opinion on Drug Safety 13:6, pages 803-830.
Read now
Read now
Marc De Hert, Johan Detraux & Joseph Peuskens. (2014) Second-generation and newly approved antipsychotics, serum prolactin levels and sexual dysfunctions: a critical literature review. Expert Opinion on Drug Safety 13:5, pages 605-624.
Read now
Read now
Leslie Citrome. (2013) Addressing the need for rapid treatment of agitation in schizophrenia and bipolar disorder: focus on inhaled loxapine as an alternative to injectable agents. Therapeutics and Clinical Risk Management 9, pages 235-245.
Read now
Read now
Ken O’Day, Krithika Rajagopalan, Kellie Meyer, Andrei Pikalov & Antony Loebel. (2013) Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US. ClinicoEconomics and Outcomes Research 5, pages 459-470.
Read now
Read now
Krithika Rajagopalan, Mariam Hassan, Ken O’Day, Kellie Meyer & Fred Grossman. (2013) Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data. Journal of Medical Economics 16:7, pages 951-961.
Read now
Read now
Leslie Citrome. (2013) New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia. Expert Review of Neurotherapeutics 13:7, pages 767-783.
Read now
Read now
Articles from other publishers (11)
Maryia Zhdanava, Swapna Karkare, Dominic Pilon, Kruti Joshi, Carmine Rossi, Laura Morrison, John Sheehan, Patrick Lefebvre, Oliver Lopena & Leslie Citrome. (2021) Prevalence of Pre-existing Conditions Relevant for Adverse Events and Potential Drug–Drug Interactions Associated with Augmentation Therapies Among Patients with Treatment-Resistant Depression. Advances in Therapy 38:9, pages 4900-4916.
Crossref
Crossref
Leslie Citrome. (2018) Reprint of: Clinical management of tardive dyskinesia: Five steps to success. Journal of the Neurological Sciences 389, pages 61-66.
Crossref
Crossref
Leslie Citrome. (2017) Clinical management of tardive dyskinesia: Five steps to success. Journal of the Neurological Sciences 383, pages 199-204.
Crossref
Crossref
L. Citrome. (2015) Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be hel. International Journal of Clinical Practice 69:9, pages 978-997.
Crossref
Crossref
R. Bordet. (2015) Quels critères pour un traitement antipsychotique idéal ?. L'Encéphale 41:1, pages 39-46.
Crossref
Crossref
George Awad, Mariam Hassan, Antony Loebel, Jay Hsu, Andrei Pikalov & Krithika Rajagopalan. (2014) Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia. BMC Psychiatry 14:1.
Crossref
Crossref
J. Peuskens, L. Pani, J. Detraux & M. De Hert. (2014) The Effects of Novel and Newly Approved Antipsychotics on Serum Prolactin Levels: A Comprehensive Review. CNS Drugs.
Crossref
Crossref
Leslie Citrome. (2013) A Review of the Pharmacology, Efficacy and Tolerability of Recently Approved and Upcoming Oral Antipsychotics: An Evidence-Based Medicine Approach. CNS Drugs 27:11, pages 879-911.
Crossref
Crossref
Leslie Citrome. (2012) Oral Antipsychotic Update: A Brief Review of New and Investigational Agents for the Treatment of Schizophrenia. CNS Spectrums 17:s1, pages 1-9.
Crossref
Crossref
Leslie Citrome. (2012) Lurasidone in Schizophrenia: New Information About Dosage and Place in Therapy. Advances in Therapy 29:10, pages 815-825.
Crossref
Crossref
Marc De Hert, Weiping Yu, Johan Detraux, Kim Sweers, Ruud van Winkel & Christoph U. Correll. (2012) Body Weight and Metabolic Adverse Effects of Asenapine, Iloperidone, Lurasidone and Paliperidone in the Treatment of Schizophrenia and Bipolar Disorder. CNS Drugs 26:9, pages 733-759.
Crossref
Crossref